When was the last time you measured your waistline? If you assume that BMI is the only number to focus on when it comes to your health, think twice. New research has revealed a shocking revelation—your waist circumference might be a far better predictor of men's cancer risk than BMI.

The study finds that for each 4-inch increase in waist size, a man's risk of cancer increases by a staggering 25%. Meanwhile, BMI, commonly regarded as the gold standard for assessing obesity, raises cancer risk by only 19% for the same weight gain. So, if you've been dismissing that pesky belly fat, it's time to take notice.

But why is your waistline so important? The reason is visceral fat—the hidden, deep fat that accumulates around your organs. Unlike other body fat, visceral fat is a stealthy troublemaker, causing inflammation, insulin resistance, and abnormal blood fat levels—all of which combine to create a cancer-perfect storm.

Obesity has been associated with an increased risk of numerous health conditions, including cancer, for decades. The research, though, indicates that a specific measure of the body—waist circumference—may be an even more reliable forecaster of cancer risk in men than the more frequently employed Body Mass Index (BMI). This finding emphasizes the need to pay particular attention to the distribution of fat and not merely to the weight of the body.

BMI has been the go-to measure for years for gauging health risks related to obesity. New research, though, that appears in The Journal of the National Cancer Institute indicates that waist measurement is a better predictor of cancer risk in men. According to the research, four more inches (10 cm) around the waist will add 25% to a man's cancer risk. Conversely, a 3.7 kg/m² rise in BMI (from a BMI of 24 to 27.7) increased cancer risk by only 19%.

Why is waist circumference a better predictor, then? Unlike BMI, which measures weight relative to height, waist circumference actually measures abdominal fat—specifically, visceral fat. This type of fat encircles internal organs and is also linked to higher levels of inflammation, insulin resistance, and abnormal blood lipids, all of which are factors in cancer growth. BMI, however, does not measure fat distribution, so two individuals with the same BMI can have very different levels of health risk depending on where fat is deposited on their bodies.

Why Men Are at Higher Risk?

Interestingly, the research identified a significant difference between men and women when it came to waist circumference and cancer risk. Although waist circumference and BMI were linked with obesity-related cancers in women, the relationship was weaker than for men. An increase of 12 cm (4.7 inches) in waist size or a 4.3 rise in BMI (from 24 to 28.3) raised the cancer risk in women by just 13%—a much lower percentage than for men.

Experts credit this difference to the way that fat is stored in the body. Men are more likely to carry fat around the abdomen, especially as visceral fat, which is more metabolically active and associated with cancer-producing biological alterations. Women, by contrast, store fat in peripheral sites such as the hips and thighs, where it is less likely to drive systemic inflammation and metabolic disturbances.

A possible reason is that men tend to depot fat more in the visceral regions, whereas women tend to carry more subcutaneous and peripheral fat," wrote the researchers. "This may render waist circumference a more robust risk factor for cancer in men and account for why waist circumference provides additional risk information beyond BMI in men but not women."

Cancer Types Most Linked to Abdominal Fat

The research used the International Agency for Research on Cancer (IARC) data to define obesity-related cancers. These cancers are esophageal (adenocarcinoma), gastric (cardia), colorectal, rectal, liver, gallbladder, pancreatic, renal, and thyroid cancers, and multiple myeloma and meningioma. In men, abdominal obesity is especially significant in raising the risk of these cancers through high levels of insulin and markers of inflammation.

For women, the research proposes that both waist circumference and hip circumference may give a more accurate estimate of visceral fat and cancer risk. "Adding hip circumference to risk models could strengthen the link between waist circumference and cancer, especially in women," researchers observed.

What This Means for Men's Health and Cancer Prevention?

With these results, doctors advise men to be more mindful of their waistline than only their BMI. Waist size is an easy method to gauge health risk, and its maintenance through lifestyle changes might be the key to cancer prevention.

How To Reduce Cancer Risk In Men?

Track Your Waist Size: Regularly measure your waist circumference and try to keep it in a healthy range (below 40 inches for men, according to medical advice).

Eat a Balanced Diet: A diet containing high fiber, lean protein, and healthy fats can assist in limiting visceral fat gain.

Exercise Consistently: Regular exercise with a combination of aerobic and strength training will help maintain a healthy waistline.

Control Stress and Sleep: Persistent stress and inadequate sleep tend to cause weight gain, especially in the midsection of the body.

Regular Health Screenings: Early identification of cancer risk factors through regular screening can greatly enhance long-term health status.

A recent meningitis outbreak in Kent University has led to many people wandering about the MenB vaccine and whether they should be getting it. The UK Health Security Agency (UKHSA) with NHS England and the government is already coordinating a targeted vaccination programme against Meningitis B- the strain identified to cause the outbreak.

Who Is Eligible for MenB Vaccine?

As per UKHSA, anyone in the following group has been offered preventative antibiotics which is also known as prophylaxis, is being offered the MenB vaccine. As of now, this includes:

• close contacts of those who are confirmed or suspected to have meningococcal disease
• students at the University of Kent who are normally resident on the Canterbury Campus, including those who may have now travelled home. Some staff living or working in these Halls of Residence have also been offered preventative antibiotics and are eligible for vaccination
• students who attend other universities in Canterbury, living in halls of residence or off-campus locations where there has been a case, and have been advised to take an antibiotic due to a close contact by UKHSA
• sixth form students (years 12 and 13) attending a secondary school or sixth form college in Kent where there has been a confirmed or probable case of meningococcal disease informed by local risk assessment
• anyone who visited or was working at Club Chemistry in Canterbury between 5 March and 15 March, when the venue closed voluntarily

Read: Fact Check: Did Keir Starmer Say UK ‘May Need To Go Into Lockdown’ If Meningitis Cases Keep Rising?

Is there Any Risk To The Public?

As of now, notes UKHSA that the risk of infection to the wider public remains low. This is because transmission of MenB requires close and prolonged contact to spread. This could only happen when people are living in the same household and with intimate contact such as kissing or sharing drinks or vapes.

The bacteria, notes UKHSA, are not as contagious as the other infections like measles and COVID 19.

Why Are Antibiotics Being Prescribed?

Antibiotics play an important role, and almost an immediate one when it comes to responding to an outbreak. For anyone who has been in close contact with a confirmed or suspected case, preventative antibiotics are being offered to them to clear any meningococcal bacteria they may be carrying. This will reduce the risk of them becoming ill or passing the bacteria on to others.

Most Commonly Asked Question: I've Had The MenACWY Vaccine, Do I Still Need MenB Vaccine?

The simple answer is a yes. UKHSA notes that if you are eligible for the MenB vaccine despite the fact that you have taken MenACWY vaccine, you should come forward and take the MenB vaccine. This is because the MenACWY vaccine does not protect you against the MenB strains, as they are both different strain. MenB has been identified as the primary cause of meningitis outbreak in Kent University.

Semaglutide is the hero ingredient in the popular drugs Ozempic (used primarily to treat Type-2 diabetes) and Wegovy (used for chronic weight management).

Semaglutide, a GLP-1 receptor agonist, has shown its prowess in lowering the risk of heart attack, stroke, or death in patients with type 2 diabetes, obesity, and heart or blood vessel disease.

With emerging preclinical evidence suggesting its potential neuroprotective and anti-inflammatory effects, an international team of researchers from the US and Taiwan focused their study on semaglutide and patients whose cancer has spread to the brain.

Cancer in the brain, also known as brain metastases, is an advanced-stage (stage IV) cancer, which is generally associated with an increased risk of morbidity and mortality in patients. Those with comorbidities like type 2 diabetes are likely to have worse outcomes.

The research, published in JAMA Network Open, showed that although the once-weekly semaglutide injections cannot directly treat cancer, they can potentially help some very ill patients live longer.

“The findings of this cohort study suggest that GLP-1 RA use was associated with a significant reduction in all-cause mortality among patients with cancer with brain metastases and type 2 diabetes, with generally consistent association across subgroups," said the team from Albert Einstein College of Medicine in New York and National Cheng Kung University Hospital in Taiwan, in the paper.

How Semaglutide Helped Patients With Brain Metastases?

The teams analyzed medical records from 151 hospitals around the world.

They identified more than 19,000 patients with cancer, brain metastases, and type 2 diabetes. Of these, 866 had been treated with a GLP-1 drug, while over 11,000 had not.

Their final analysis included two groups of 850 patients who were compared for the effects of semaglutide and were followed for up to three years after their brain metastases were first recorded.

The patients taking semaglutide were significantly less likely to die -- about 37 percent -- during the follow-up period than those who were not.

The pattern was fairly consistent across several major cancer types, including lung cancer, breast cancer, and melanoma.

"These results build upon existing evidence that GLP-1 receptor activation modulates pathways relevant to neuro-oncologic health, including attenuation of neuroinflammation, preservation of blood–brain barrier integrity, and reduction of oxidative stress and mitochondrial dysfunction," the researchers said.

However, they also acknowledged limitations, such as the study was retrospectively conducted, which checked medical records and did not test patients in a controlled trial.

Ozempic Goes Generic, To Cost Less By 90%

With Novo Nordisk losing its patent in many countries, the sky-high prices of Ozempic and Wegovy are likely to go down by 90 percent.

This means the drug will be available at cheaper rates to 40 per cent of the world's population.

In India, the patent ended on March 20, and since then, several companies, including Alkem Laboratories, NATCO Pharma, Eris Lifesciences, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Glenmark Pharmaceuticals, have launched their generic versions of semaglutide at a reduced price.

Also read: Semaglutide Becomes Cheap In India: A Gamechanger Or Health Gamble?

Who Should Avoid Semaglutide?

Semaglutide should be avoided or used with extreme caution in:

• Patients with a history of medullary thyroid carcinoma
• Individuals with a history of pancreatitis
• Those with severe gastrointestinal disease (e.g., gastroparesis)
• Pregnant or breastfeeding women
• Patients with Type 1 diabetes
• Patients with severe eye problems due to diabetes (can be taken with care)
• Individuals seeking purely cosmetic weight loss without a medical indication.

Living in more intensely developed neighborhoods may actually protect you against a stroke, a new University of Michigan study suggests.

Researchers tracked more than 25,000 adults across the US for over a decade and have now found that residents in areas with higher levels of development with more buildings, sidewalks and infrastructure, had a 2.5 percent lower risk of suffering a first-time stroke compared to residents in less developed areas.

Cathy Antonakos, research specialist senior in the U-M School of Kinesiology and first author explained: ""High-intensity development typically includes greater housing density and more commercial/retail outlets.

"These areas are more likely to feature compact land uses with access to health care, food stores, public transport and physical activity infrastructure like sidewalks, bike facilities and parks."

However, the study did not examine these environmental features, but there are some practical applications, Antonakos noted.

"For physicians, the study suggests that neighborhood-level factors may influence first-time stroke risk, in addition to individual-level factors," she said. "For planners, the findings suggest that enhancing environments with features that support cardiovascular health and physical activity may help lower the risk of first-time stroke."

Strokes: A Rising Crisis In India

Heart strokes are also one of the leading global health burdens, causing significant deaths and disability worldwide, including in India. Compared to Western countries, stroke also tends to occur at a younger age and is associated with a higher case fatality rate in the country.

One in seven stroke patients in India are young adults aged below 45 years, with hypertension leading as the major risk factor, according to a study by the Indian Council of Medical Research (ICMR).

The Global Burden of Disease Study 2021 identified hypertension, air pollution, tobacco smoking, high cholesterol, increased salt intake, and diabetes as the leading risk factors of stroke.

Incidence of stroke is increasing significantly in low- and middle-income countries (LMICs), especially in India, due to population growth, aging, and greater exposure to risk factors.

Wine Reduces Your Risk Of Strokes

A new global study suggests that moderately drinking wine can decrease your risk dying from cardiovascular disease by 21 percent.

A group of Chinese researchers who analyzed 340,924 adults in the UK between 2006 and 2022 classified a 12-ounce beer, a 5-ounce glass of wine or a 1.5-ounce shot of liquor each contains about 14 grams of pure alcohol.

Those who consumed less than 20 grams per week, about 1.5 standard drinks, were classified as never or occasional drinkers. The low alcohol consumption group included men who drank more than 20 grams per week but no more than 20 grams per day, and women who drank between 10 grams per day and 20 grams per week.

They found those with high alcohol consumption were 24 percent more likely to die from any cause, 36 percent more likely to die from cancer and 14 percent more likely to die from heart disease.

Additionally, even low intake of spirits such as beer or cider was associated with a nine percent higher risk of dying from cardiovascular disease compared with drinking never or occasionally.